UK markets open in 4 hours 4 minutes
  • NIKKEI 225

    23,186.71
    -145.23 (-0.62%)
     
  • HANG SENG

    24,578.74
    -7.86 (-0.03%)
     
  • CRUDE OIL

    36.33
    +0.16 (+0.44%)
     
  • GOLD FUTURES

    1,877.00
    +9.00 (+0.48%)
     
  • DOW

    26,659.11
    +139.16 (+0.52%)
     
  • BTC-GBP

    10,378.29
    -51.74 (-0.50%)
     
  • CMC Crypto 200

    263.11
    +20.43 (+8.42%)
     
  • ^IXIC

    11,185.59
    +180.72 (+1.64%)
     
  • ^FTAS

    3,152.13
    -3.12 (-0.10%)
     

Worldwide Anti-Viral Therapies Industry to 2027 - by Type, Mechanism of Action, Application and Geography

Research and Markets
·6-min read

Dublin, Sept. 28, 2020 (GLOBE NEWSWIRE) -- The "Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; Mechanism of Action; Application and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the market is expected to reach US$ 76,282.63 million by 2027 from US$ 40,589.79 million in 2019; it is estimated to grow at a CAGR of 8.3% from 2020 to 2027. The report highlights trends prevailing in the global anti - viral therapies market and the drivers and restraints pertaining to the market growth.

Based on type, the global anti - viral therapies market is segmented into generic drugs and branded drugs. The generic drugs segment is estimated to register a higher CAGR in the market during 2020-2027. Rising demand for low-cost drugs, growing number of FDA-approved generic drugs, rising adoption in emerging nations, and patent expiry of various branded products are the factors boosting the market for the generic drugs segment.

The global anti - viral therapies market growth is mainly attributed to factors such as increasing R&D expenditure in pharmaceutical companies and rising government support for research activities and clinical trials. However, high drug development cost hinders the growth of the market.

AbbVie Inc.; Abbott; Astrazeneca; F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc; and Aurobindo Pharma are among the leading companies operating in the anti - viral therapies market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the anti - viral therapies market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global anti - viral therapies market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Anti - Viral Therapies Market - By Type
1.3.2 Global Anti - Viral Therapies Market - By Mechanism of Action
1.3.3 Global Anti-viral therapies market - By Application
1.3.4 Global Anti - Viral Therapies Market - By Geography

2. Anti-Viral Therapies Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Anti-Viral Therapies - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South and Central America (SCAM) - PEST Analysis
4.3 Expert Opinions

5. Anti-Viral Therapies Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing R&D Expenditures in Pharmaceutical Companies
5.1.2 Rising Government Support for Research Activities and Clinical Trials
5.2 Market Restraints
5.2.1 High Cost of Drug Development
5.3 Market Opportunities
5.3.1 Emerging Markets
5.4 Future Trends
5.4.1 Growing Emphasis on Launching Anti-Viral Agents
5.5 Impact analysis

6. Anti-Viral Therapies Market - Global Analysis
6.1 Global Anti-Viral Therapies Market Revenue Forecast And Analysis
6.2 Global Anti- Viral Therapies Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Anti - Viral Therapies Market Analysis - By Type
7.1 Overview
7.2 Anti-viral therapies market Revenue Share, by Type (2019 and 2027)
7.3 Generic Drugs
7.3.1 Overview
7.3.2 Generic Drugs: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Branded Drugs
7.4.1 Overview
7.4.2 Branded Drugs: Anti-viral therapies market - Revenue and Forecast to 2027 (US$ Million)

8. Anti-Viral Therapies Market Analysis - By Mechanism of Action
8.1 Overview
8.2 Anti-Viral Therapies Market Revenue Share, by Mechanism Of Action (2019 and 2027)
8.3 Nucleotide Polymerase Inhibitor
8.3.1 Overview
8.3.2 Nucleotide Polymerase Inhibitor: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Reverse Transcriptase Inhibitors
8.4.1 Overview
8.4.2 Reverse Transcriptase Inhibitors: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Protease Inhibitors
8.5.1 Overview
8.5.2 Protease Inhibitors: Anti-viral therapies market - Revenue and Forecast to 2027 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Anti-viral therapies market - Revenue and Forecast to 2027 (US$ Million)

9. Anti-Viral Therapies Market Analysis - By Application
9.1 Overview
9.2 Anti-Viral Therapies Market Share, by Application, 2019 and 2027, (%)
9.3 HIV
9.3.1 Overview
9.3.2 HIV: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Hepatitis
9.4.1 Overview
9.4.2 Hepatitis: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
9.5 Herpes
9.5.1 Overview
9.5.2 Herpes: Anti-viral therapies market - Revenue and Forecast to 2027 (US$ Million)
9.6 Influenza
9.6.1 Overview
9.6.2 Influenza: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)
9.7 Other Applications
9.7.1 Overview
9.7.2 Other Applications: Anti-Viral Therapies Market - Revenue and Forecast to 2027 (US$ Million)

10. Anti-Viral Therapies Market - Geographic Analysis
10.1 North America: Anti-Viral Therapies Market
10.2 Europe: Anti-Viral Therapies Market
10.3 Asia Pacific: Anti-Viral Therapies Market
10.4 Middle East & Africa: Anti-Viral Therapies Market
10.5 South and Central America: Anti-Viral Therapies Market

11. Impact of COVID-19 Pandemic on Global Anti-Viral Therapies Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of World: Impact Assessment of COVID-19 Pandemic

12. Anti-Viral Therapies Market - Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview

13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 AbbVie Inc.
13.3 Bristol-Myers Squibb Company
13.4 Johnson and Johnson Services, Inc.
13.5 Merck & Co., Inc.
13.6 Gilead Sciences, Inc.
13.7 GlaxoSmithKline plc.
13.8 AstraZeneca
13.9 Aurobindo Pharma Ltd
13.10 F. HOFFMANN-LA ROCHE LTD.

14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/qze8sm

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900